financetom
Personal Finance
financetom
/
Personal Finance
/
Research Alert: CFRA Keeps Hold Opinion On Shares Of T. Rowe Price Group, Inc.
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Research Alert: CFRA Keeps Hold Opinion On Shares Of T. Rowe Price Group, Inc.
Mar 13, 2024 11:21 PM

01:50 AM EDT, 03/14/2024 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

We raise our 12-month target price by $10 to $122, valuing TROW at 15.3x our 2025 adjusted EPS estimate of $7.95 (lifted today by $0.30) and at 15.6x our 2024 EPS estimate of $7.80 (upped by $0.40), versus the shares' 3-year average forward multiple of 14.9x and the 12.6x average forward multiple of TROW's closest asset manager peers. We expect revenues in 2024 will be flat to up 5%, and will rise by 1% to 5% in 2025. Revenues in 2023 declined by 0.4%, better than our forecasted decline of 6% to 10%, as a 3.7% decline in investment advisory fees (TROW's main revenue source) was partly offset by a turnaround in performance based revenues. Assets under management (AUM) of $1.44 trillion as of December 31, 2023 rose by 13.3% year-over-year on market appreciation, partly offset by $82 billion of net client outflows. Weighing TROW's premium valuation versus peers with its subpar fund flow trends, we view the shares as fairly valued.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Research Alert: CFRA Raises Opinion On Shares Of Johnson & Johnson To Buy From Hold
Research Alert: CFRA Raises Opinion On Shares Of Johnson & Johnson To Buy From Hold
Oct 14, 2025
11:05 AM EDT, 10/14/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: After Q3 earnings and the announcement of the separation of Orthopedics, we raise our target to $220 from $166. This is based on 19.2x our 2026 EPS estimate and is...
Research Alert: CFRA Keeps Strong Buy Opinion On Adss Of Astrazeneca
Research Alert: CFRA Keeps Strong Buy Opinion On Adss Of Astrazeneca
Oct 13, 2025
06:20 AM EDT, 10/13/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We revised our target price to USD98 (up from USD86), which implies 19.3x our 2026 EPADS estimate, largely in line with its five-year historical forward P/E. On October 10, U.S....
Research Alert: CFRA Keeps Hold Opinion On Class B Shares Of Berkshire Hathaway Inc.
Research Alert: CFRA Keeps Hold Opinion On Class B Shares Of Berkshire Hathaway Inc.
Oct 12, 2025
01:00 AM EDT, 10/13/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We raise our 12-month target price by $15 to $510, valuing Berkshire's class B shares at 23x our 2026 operating EPS estimate of $21.80, versus their three-year average forward multiple...
Research Alert: CFRA Maintains Buy Opinion On Shares Of Jpmorgan Chase & Co.
Research Alert: CFRA Maintains Buy Opinion On Shares Of Jpmorgan Chase & Co.
Oct 14, 2025
12:20 PM EDT, 10/14/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We keep our 12-month target price at $340, applying a forward P/E of 15.5x, near the three-year historical average at 15.0x on normalized earnings. We keep our EPS estimates at...
Copyright 2023-2025 - www.financetom.com All Rights Reserved